What do systematic reviews say?

Atypical antipsychotics vs placebo

• Antipsychotics for agitation and psychosis in people with Alzheimer's disease and vascular dementia 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  High

Atypical antipsychotics vs placebo

• Antipsychotics for agitation and psychosis in people with Alzheimer's disease and vascular dementia 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  Moderate

Summary of findings ‐ Typical antipsychotics vs placebo

• Antipsychotics for agitation and psychosis in people with Alzheimer's disease and vascular dementia 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  Moderate

Summary of findings ‐ Typical antipsychotics vs placebo

• Antipsychotics for agitation and psychosis in people with Alzheimer's disease and vascular dementia 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  Low

Summary of findings ‐ Typical antipsychotics vs placebo

• Antipsychotics for agitation and psychosis in people with Alzheimer's disease and vascular dementia 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  Low

Summary of findings ‐ Typical antipsychotics vs placebo

• Antipsychotics for agitation and psychosis in people with Alzheimer's disease and vascular dementia 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  High

Summary of findings ‐ Typical antipsychotics vs placebo

• Antipsychotics for agitation and psychosis in people with Alzheimer's disease and vascular dementia 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  Moderate

Summary of findings ‐ Typical antipsychotics vs placebo

• Antipsychotics for agitation and psychosis in people with Alzheimer's disease and vascular dementia 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  Low

Atypical antipsychotics vs placebo

• Antipsychotics for agitation and psychosis in people with Alzheimer's disease and vascular dementia 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  Moderate

Atypical antipsychotics vs placebo

• Antipsychotics for agitation and psychosis in people with Alzheimer's disease and vascular dementia 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  Moderate

Donepezil 5 mg vs placebo

• Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta‐analysis 2021 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 1601 participants
  High

Donepezil 10 mg/day vs placebo

Donepezil 10 mg showed no clear difference in serious adverse events (excluding death) at 24 weeks compared with placebo (moderate certainty).

• Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta‐analysis 2021 · Cochrane Headline outcomes only
  OR 1.15 [0.81, 1.64]
  2 studies · 813 participants
  Moderate

Rivastigmine vs placebo

• Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta‐analysis 2021 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 748 participants
  Low

Rivastigmine vs placebo

• Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta‐analysis 2021 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 800 participants
  Low

Rivastigmine vs placebo

It is very uncertain whether rivastigmine changes adverse events (all adverse events) at 24 to 26 weeks compared with placebo (very low certainty).

• Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta‐analysis 2021 · Cochrane Headline outcomes only
  OR 3.21 [0.36, 28.88]
  3 studies · 831 participants
  Very low

Rivastigmine vs placebo

Rivastigmine showed no clear difference in serious adverse events (excluding death) at 24 to 26 weeks compared with placebo (low certainty).

• Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta‐analysis 2021 · Cochrane Headline outcomes only
  OR 1.42 [0.9, 2.25]
  2 studies · 622 participants
  Low

Galantamine vs placebo

• Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta‐analysis 2021 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 1188 participants
  Moderate

Galantamine vs placebo

Galantamine leads to higher clinical global impression: CIBIC‐Plus (Improvement) at 26 weeks compared with placebo (high certainty).

• Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta‐analysis 2021 · Cochrane Headline outcomes only
  OR 1.32 [1.03, 1.7]
  2 studies · 1326 participants
  High

Galantamine vs placebo

• Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta‐analysis 2021 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 1174 participants
  Low

Galantamine vs placebo

Galantamine probably leads to higher adverse events (all adverse events) at 26 weeks compared with placebo (moderate certainty).

• Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta‐analysis 2021 · Cochrane Headline outcomes only
  OR 1.57 [1.02, 2.43]
  2 studies · 1378 participants
  Moderate